Food-contact packaging manufactured before 12 August 2026 does not receive an automatic stock-exhaustion exemption under the PPWR. Packaging first placed on the EU market from that date must meet the Article 5(5) PFAS limits, while packaging already placed on the market before 12 August 2026 may remain. The decisive buyer variable is the placing-on-the-market event, rather than the production date or warehouse age. Buyers should link each inventory group to its packaging type, revision, lot, placement evidence and, where post-deadline status applies or the timing cannot be demonstrated, current PFAS evidence for the exact commercial construction.

The First Release Question Is When the Packaging Was Placed on the Market

Regulation (EU) 2025/40 on packaging and packaging waste defines “placing on the market” as the first making available of packaging, empty or with a product, on the Union market. Article 5(5) applies from 12 August 2026.

The European Commission’s June 2026 guidance then addresses the stock question directly: packaging containing PFAS that was produced before 12 August 2026 receives no separate transition period for exhausting inventory. Packaging placed on the market before that date may remain; packaging placed on the market afterward must comply with the applicable PFAS limits. The guidance also states that recycled material receives no special exception.

This creates a practical release matrix.

A manufacturing certificate can establish when a package was produced.

A warehouse receipt can establish when inventory reached a facility.

Neither automatically establishes when that packaging was first placed on the Union market.

That distinction is the core of the release decision.

Which Event Counts as Placing the Packaging on the Market?

The correct timestamp depends on the type of packaging and supply route.

The European Commission PPWR guidance on PFAS enforcement and exhaustion of stocks explains that, in general, sales and grouped food-contact packaging are placed on the market when filled where final processing such as sealing may influence compliance. Transport and service packaging are generally placed on the market empty. For imported packaging or packaged products, the relevant timestamp is release for free circulation at the end of the customs procedure.

This means one company may have several “pre-August” inventory groups with different regulatory outcomes.

A converter may have manufactured empty packaging in July.

A filler may still hold it in August.

An imported packaged product may have been manufactured outside the EU months earlier but released for free circulation after 12 August.

The production date is the same type of data in each case. Its regulatory decision value is different.

What Evidence Can Support Pre-Deadline Stock Status?

The objective is to build a traceable relationship:

Packaging identity → Revision → Lot or inventory group → Relevant placement event → Date → Supporting record

For companies managing a broader PPWR evidence system, ChemicalCell’s PPWR packaging documentation, testing and supplier-qualification framework explains how packaging identity, BOM, material evidence, traceability, commercial production and change control should remain connected.

For the stock-exhaustion question, only evidence relevant to the placement decision should be reviewed.

More documents do not automatically create a stronger conclusion.

The evidence must describe the same packaging inventory.

A customs record for Shipment A does not establish the status of Shipment B. An invoice for one packaging revision should not be extended to a later revision simply because the commercial product name stayed unchanged.

Why a COA or “PFAS-Free” Statement Cannot Resolve the Stock Question

COA review and market-placement review answer different questions.

A conventional COA usually supports batch-release variables such as appearance, dimensions, coating weight, solids, viscosity, mechanical properties or other agreed quality parameters. It may show that a supplied lot meets the purchasing specification.

It usually does not establish:

• when the package was placed on the EU market;
• whether every layer of the finished package meets Article 5(5);
• whether a historical lot used the same formulation as the current product;
• whether an ink, adhesive, coating or processing input changed;
• whether a supplier declaration covers the relevant manufacturing period.

A supplier statement such as “PFAS-free” or “no intentionally added PFAS” has another boundary. It can support formulation knowledge when the product, definition, revision and effective period are clearly identified. It does not automatically establish concentration compliance for the finished food-contact packaging.

This creates an important buyer distinction:

COA → batch quality

Supplier declaration → defined formulation knowledge

Placement evidence → inventory transition status

Analytical result → measured PFAS decision within the method and sample scope

Using one of these documents as a substitute for another can produce a formally complete file with a weak release decision.

When Does Current PFAS Testing Enter the Decision?

If the packaging was first placed on the market after 12 August 2026, Article 5(5) becomes the relevant concentration decision.

The Regulation establishes:

• 25 ppb for any individual PFAS measured by targeted PFAS analysis, excluding polymeric PFAS from quantification;
• 250 ppb for the sum of targeted PFAS, where applicable with prior degradation of precursors, excluding polymeric PFAS;
• 50 ppm for PFAS including polymeric PFAS.

Testing becomes relevant when the buyer needs to answer:

Does the exact commercial packaging being placed on the market satisfy the applicable concentration requirements?

That is a different task from deciding whether stock qualifies as pre-deadline inventory.

The analytical details should remain on the dedicated ChemicalCell page How Should PFAS in Food-Contact Packaging Be Verified Under the EU PPWR?, which covers analytical scope, total fluorine, targeted PFAS, precursor treatment, polymer-inclusive evidence and commercial-package representativeness.

For this stock-release page, the approval logic is narrower:

Pre-deadline placement proven → stock-status decision

Post-deadline placement → current PFAS compliance decision

Placement date unresolved → close the traceability gap or assess against the current PFAS requirements

Testing should not be ordered simply because a document is missing. It should close a defined decision gap.

Why Testing One Raw Material May Still Be Insufficient

A technically valid result can still describe the wrong object.

Consider a multilayer food-contact package containing:

• substrate;
• barrier coating;
• printing ink;
• adhesive;
• heat-seal layer;
• primer or surface treatment.

A PFAS report for the barrier coating establishes information about that tested coating sample.

It does not automatically establish the concentration status of the complete commercial package.

The reverse risk also matters. An acceptable COA for a coating or polymer does not control PFAS contribution that may arise from another component or formulation input outside the COA scope.

The decision relationship should remain:

Potential fluorinated input or unresolved source → Finished-package concentration risk → Appropriate analytical evidence → Commercial-package decision

For stock release, analytical evidence is useful only when it can be connected to the inventory that actually needs a post-deadline compliance conclusion.

Can One Historical PFAS Report Cover All Remaining Inventory?

Only when the tested configuration is representative of the inventory being released.

This is where apparently simple “old stock” projects often become supplier-qualification projects.

A warehouse may contain one commercial packaging code while the underlying material history includes:

• several coating formulations;
• different adhesive suppliers;
• different ink systems;
• two converting sites;
• recycled and virgin substrate versions;
• a process-aid change;
• several packaging revisions.

A historical test should therefore be linked through:

Tested sample → Packaging revision → Component/BOM status → Supplier/site → Commercial lot or inventory group

A report remains analytically valid as a report even after a formulation change. Its value for the current release decision may no longer be the same.

The same principle applies to supplier declarations. A current PFAS statement cannot automatically be applied retrospectively to historical inventory unless its scope explicitly covers those historical formulations and supply periods.

ChemicalCell’s PFAS product tracking and change-control framework addresses this version problem in more detail, including commercial grade, formulation revision, manufacturing source, market scope and effective period.

When Should the Supplier Be Requalified?

A stock review should trigger supplier or packaging requalification when the evidence shows that the previously approved state has changed.

Examples include:

Change control protects the validity of the original approval.

It should answer:

Has anything changed that could make the evidence attached to this packaging version no longer representative?

A stable COA does not eliminate this question. Conventional release parameters can remain unchanged while formulation or source information relevant to PFAS assessment changes.

When Does Old-Stock Uncertainty Become a Second-Source Decision?

Second-source qualification becomes relevant only after the stock decision exposes a supply problem.

Typical examples are:

• remaining inventory cannot be supported as pre-deadline stock;
• current packaging cannot generate sufficient PFAS evidence;
• a supplier cannot provide revision or effective-period traceability;
• a formulation must change to maintain post-deadline supply;
• an alternative coating, adhesive or other functional material is required.

At that point, the buyer should avoid comparing second sources only by price, trade name or ordinary COA limits.

The comparison should preserve:

Functional specification + PFAS evidence + Commercial grade identity + Manufacturing source + Sample equivalence + Commercial-lot control + Change notification

A development sample can prove that a candidate is worth evaluating.

It cannot prove that routine commercial supply will remain equivalent.

Before approving a replacement, buyers should connect the evaluated sample to the intended commercial grade, supplier, manufacturing site, formulation revision and future change-control agreement.

This keeps second-source qualification downstream of the stock question rather than turning this page into a general PFAS-free material-selection guide.

A Practical PPWR PFAS Stock-Release Decision

For each inventory group, the buyer can use the following sequence.

The decision should end in one of three states:

Release on supported pre-deadline status

Use when the relevant placement event occurred before 12 August 2026 and can be connected to the specific inventory.

Release only after current PFAS verification

Use when the packaging is first placed on the market from 12 August 2026 and the required evidence supports the exact commercial configuration.

Keep approval open

Use when placement timing, packaging identity, evidence scope, sample representativeness or revision history remains unresolved.

“Old stock” should never be the approval category by itself.

What Should Buyers Prepare Before a Technical or Supplier Discussion?

When a stock-status problem needs escalation, prepare the evidence around the decision rather than sending a folder of unrelated certificates.

The useful package includes:

• food-contact packaging type and intended EU supply route;
• packaging code and revision;
• production lot and quantity;
• manufacturing date;
• claimed placing-on-market date;
• document supporting that placement event;
• import/customs record where relevant;
• supplier and manufacturing site;
• BOM or relevant coating/adhesive/ink information;
• PFAS declaration with defined product and effective period;
• available analytical reports;
• identity of the tested sample;
• known formulation, supplier or site changes;
• expected replacement or second-source requirement if existing stock cannot be supported.

If the review shows that a new material, alternative supplier or replacement commercial grade is required, the next step is specification comparison and sample qualification rather than another generic compliance statement.

Relevant material, specification, documentation, sample and quantity requirements can be submitted through the ChemicalCell RFQ form. The inquiry should identify the packaging component or raw material being replaced, its intended function, current specification, available PFAS evidence, target market, expected quantity and any second-source qualification requirements.

The central buyer rule after 12 August 2026 is straightforward:

Production date tells you when the packaging was made.

Market-placement evidence tells you whether the stock transition question applies.

PFAS evidence tells you whether post-deadline packaging can meet the concentration decision.

Keeping those three decisions separate gives QA, regulatory and procurement teams a much stronger basis for releasing legacy inventory, identifying evidence gaps and deciding when a supplier or second source needs qualification.